IL-10 and IL-10 inducing agents along with immunosuppressants, anti-CD3 antibodies, and tolerogenic DCs have shown promising results in Tr1 induction and GVHD prevention [89,90,95,96]. Here, IL10 is linked to graft versus host disease.